Drug profile
Etrasimod
GenericRadar assessment
Patent Radar Assessment
Grade A2
United States · 2030 Radar
Verification
MEDIUM
Why Grade A?
Current Orange Book-derived VELSIPITY record lists US8580841 as a Substance/Product patent expiring 2030-03-05.
Core Patent Expiry
2030-03-05
2030 Target Event
US8580841
Drug Substance / Drug Product · 2030-03-05
Core API Event?
Yes
Later Blocking Patents
Yes. Additional VELSIPITY substance patents extend to 2036.
Generic Entry Assessment
Useful early DS milestone, but later 2036 substance patents mean 2030 is not the final protection horizon.
Patent landscape
| Country | Patent no. | Type | Expiry | Status | Verified | Opportunity |
|---|---|---|---|---|---|---|
| United States | US8580841 | Drug Substance / Drug Product | 2030-03-05 | Protected | Yes | 58 |
API sourcing
Regulatory filing labels distinguish verified/listed records from records that have not yet been verified. “Not verified” does not mean that a filing does not exist.
| API | Manufacturer | Country | US DMF | KDMF | Japan MF | CEP | EU GMP | Status |
|---|---|---|---|---|---|---|---|---|
| Etrasimod arginine | Cipla | India | Not verified | Not verified | Not verified | Not verified | Not verified | Listed supplier / verify filing |
| Etrasimod arginine | Curia | United States | Not verified | Not verified | Not verified | Not verified | Not verified | Listed supplier / verify filing |
| Etrasimod arginine | Maithri Drugs | India | Not verified | Not verified | Not verified | Not verified | Not verified | Listed supplier / verify filing |